1
|
Nan Y, Ser JD, Walsh S, Schönlieb C, Roberts M, Selby I, Howard K, Owen J, Neville J, Guiot J, Ernst B, Pastor A, Alberich-Bayarri A, Menzel MI, Walsh S, Vos W, Flerin N, Charbonnier JP, van Rikxoort E, Chatterjee A, Woodruff H, Lambin P, Cerdá-Alberich L, Martí-Bonmatí L, Herrera F, Yang G. Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions. AN INTERNATIONAL JOURNAL ON INFORMATION FUSION 2022; 82:99-122. [PMID: 35664012 PMCID: PMC8878813 DOI: 10.1016/j.inffus.2022.01.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 12/22/2021] [Accepted: 01/07/2022] [Indexed: 05/13/2023]
Abstract
Removing the bias and variance of multicentre data has always been a challenge in large scale digital healthcare studies, which requires the ability to integrate clinical features extracted from data acquired by different scanners and protocols to improve stability and robustness. Previous studies have described various computational approaches to fuse single modality multicentre datasets. However, these surveys rarely focused on evaluation metrics and lacked a checklist for computational data harmonisation studies. In this systematic review, we summarise the computational data harmonisation approaches for multi-modality data in the digital healthcare field, including harmonisation strategies and evaluation metrics based on different theories. In addition, a comprehensive checklist that summarises common practices for data harmonisation studies is proposed to guide researchers to report their research findings more effectively. Last but not least, flowcharts presenting possible ways for methodology and metric selection are proposed and the limitations of different methods have been surveyed for future research.
Collapse
Affiliation(s)
- Yang Nan
- National Heart and Lung Institute, Imperial College London, London, Northern Ireland UK
| | - Javier Del Ser
- Department of Communications Engineering, University of the Basque Country UPV/EHU, Bilbao 48013, Spain
- TECNALIA, Basque Research and Technology Alliance (BRTA), Derio 48160, Spain
| | - Simon Walsh
- National Heart and Lung Institute, Imperial College London, London, Northern Ireland UK
| | - Carola Schönlieb
- Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, Northern Ireland UK
| | - Michael Roberts
- Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, Northern Ireland UK
- Oncology R&D, AstraZeneca, Cambridge, Northern Ireland UK
| | - Ian Selby
- Department of Radiology, University of Cambridge, Cambridge, Northern Ireland UK
| | - Kit Howard
- Clinical Data Interchange Standards Consortium, Austin, TX, United States of America
| | - John Owen
- Clinical Data Interchange Standards Consortium, Austin, TX, United States of America
| | - Jon Neville
- Clinical Data Interchange Standards Consortium, Austin, TX, United States of America
| | - Julien Guiot
- University Hospital of Liège (CHU Liège), Respiratory medicine department, Liège, Belgium
- University of Liege, Department of clinical sciences, Pneumology-Allergology, Liège, Belgium
| | - Benoit Ernst
- University Hospital of Liège (CHU Liège), Respiratory medicine department, Liège, Belgium
- University of Liege, Department of clinical sciences, Pneumology-Allergology, Liège, Belgium
| | | | | | - Marion I. Menzel
- Technische Hochschule Ingolstadt, Ingolstadt, Germany
- GE Healthcare GmbH, Munich, Germany
| | - Sean Walsh
- Radiomics (Oncoradiomics SA), Liège, Belgium
| | - Wim Vos
- Radiomics (Oncoradiomics SA), Liège, Belgium
| | - Nina Flerin
- Radiomics (Oncoradiomics SA), Liège, Belgium
| | | | | | - Avishek Chatterjee
- Department of Precision Medicine, Maastricht University, Maastricht, The Netherlands
| | - Henry Woodruff
- Department of Precision Medicine, Maastricht University, Maastricht, The Netherlands
| | - Philippe Lambin
- Department of Precision Medicine, Maastricht University, Maastricht, The Netherlands
| | - Leonor Cerdá-Alberich
- Medical Imaging Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Luis Martí-Bonmatí
- Medical Imaging Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Francisco Herrera
- Department of Computer Sciences and Artificial Intelligence, Andalusian Research Institute in Data Science and Computational Intelligence (DaSCI) University of Granada, Granada, Spain
- Faculty of Computing and Information Technology, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Guang Yang
- National Heart and Lung Institute, Imperial College London, London, Northern Ireland UK
- Cardiovascular Research Centre, Royal Brompton Hospital, London, Northern Ireland UK
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, Northern Ireland UK
| |
Collapse
|
2
|
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib. PLoS One 2015; 10:e0130700. [PMID: 26107615 PMCID: PMC4480971 DOI: 10.1371/journal.pone.0130700] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2014] [Accepted: 05/23/2015] [Indexed: 01/21/2023] Open
Abstract
Development of drug responsive biomarkers from pre-clinical data is a critical step in drug discovery, as it enables patient stratification in clinical trial design. Such translational biomarkers can be validated in early clinical trial phases and utilized as a patient inclusion parameter in later stage trials. Here we present a study on building accurate and selective drug sensitivity models for Erlotinib or Sorafenib from pre-clinical in vitro data, followed by validation of individual models on corresponding treatment arms from patient data generated in the BATTLE clinical trial. A Partial Least Squares Regression (PLSR) based modeling framework was designed and implemented, using a special splitting strategy and canonical pathways to capture robust information for model building. Erlotinib and Sorafenib predictive models could be used to identify a sub-group of patients that respond better to the corresponding treatment, and these models are specific to the corresponding drugs. The model derived signature genes reflect each drug’s known mechanism of action. Also, the models predict each drug’s potential cancer indications consistent with clinical trial results from a selection of globally normalized GEO expression datasets.
Collapse
|
3
|
Tomescu OA, Mattanovich D, Thallinger GG. Integrative omics analysis. A study based on Plasmodium falciparum mRNA and protein data. BMC SYSTEMS BIOLOGY 2014; 8 Suppl 2:S4. [PMID: 25033389 PMCID: PMC4101701 DOI: 10.1186/1752-0509-8-s2-s4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Background Technological improvements have shifted the focus from data generation to data analysis. The availability of large amounts of data from transcriptomics, protemics and metabolomics experiments raise new questions concerning suitable integrative analysis methods. We compare three integrative analysis techniques (co-inertia analysis, generalized singular value decomposition and integrative biclustering) by applying them to gene and protein abundance data from the six life cycle stages of Plasmodium falciparum. Co-inertia analysis is an analysis method used to visualize and explore gene and protein data. The generalized singular value decomposition has shown its potential in the analysis of two transcriptome data sets. Integrative Biclustering applies biclustering to gene and protein data. Results Using CIA, we visualize the six life cycle stages of Plasmodium falciparum, as well as GO terms in a 2D plane and interpret the spatial configuration. With GSVD, we decompose the transcriptomic and proteomic data sets into matrices with biologically meaningful interpretations and explore the processes captured by the data sets. IBC identifies groups of genes, proteins, GO Terms and life cycle stages of Plasmodium falciparum. We show method-specific results as well as a network view of the life cycle stages based on the results common to all three methods. Additionally, by combining the results of the three methods, we create a three-fold validated network of life cycle stage specific GO terms: Sporozoites are associated with transcription and transport; merozoites with entry into host cell as well as biosynthetic and metabolic processes; rings with oxidation-reduction processes; trophozoites with glycolysis and energy production; schizonts with antigenic variation and immune response; gametocyctes with DNA packaging and mitochondrial transport. Furthermore, the network connectivity underlines the separation of the intraerythrocytic cycle from the gametocyte and sporozoite stages. Conclusion Using integrative analysis techniques, we can integrate knowledge from different levels and obtain a wider view of the system under study. The overlap between method-specific and common results is considerable, even if the basic mathematical assumptions are very different. The three-fold validated network of life cycle stage characteristics of Plasmodium falciparum could identify a large amount of the known associations from literature in only one study.
Collapse
|